ULO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ULO (ULO).
ULO is a brand name for the drug ublituximab, a monoclonal antibody that targets CD20 on B-cells, leading to B-cell lysis via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
| Metabolism | Catabolized via reticuloendothelial system; not metabolized by CYP450 enzymes. |
| Excretion | Primarily renal (60-80% as unchanged drug) via glomerular filtration and active tubular secretion; remainder as inactive metabolites. Biliary/fecal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life is 1.5-3 hours (mean 2.2 hours) in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <15 mL/min), necessitating dose adjustment. |
| Protein binding | 85-95% bound primarily to albumin (and to a lesser extent alpha-1-acid glycoprotein). |
| Volume of Distribution | 0.3-0.5 L/kg (mean 0.4 L/kg), indicating distribution mainly in extracellular fluid and well-perfused tissues. |
| Bioavailability | Oral: 70-85%; Intramuscular: 90-100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-15 minutes; Intramuscular: 10-30 minutes. |
| Duration of Action | Oral/IV/IM: 4-8 hours, depending on dose and renal function; hepatic impairment does not significantly prolong duration. |
| Molecular Weight | 475.62 |
100 mg orally twice daily for 7 days
| Dosage form | SYRUP |
| Renal impairment | No adjustment required for GFR >=30 mL/min; not recommended for GFR <30 mL/min |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established |
| Geriatric use | No specific dose adjustment; use with caution due to age-related renal decline |
| 1st trimester | Ulipristal acetate is contraindicated in pregnancy; no adequate data in first trimester. |
| 2nd trimester | Contraindicated; potential fetal harm, including abortifacient effects. |
| 3rd trimester | Contraindicated; may cause premature labor or fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for ULO (ULO).
| Placental transfer | Crosses placenta; high affinity for progesterone receptors. |
| Breastfeeding | Ulipristal acetate is excreted in breast milk; theoretical risk of hormonal effects. Avoid breastfeeding for 1 week after dose. |
| Lactation Rating | L4 (Probably Hazardous) |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyBreastfeeding (unless temporary cessation)Known hypersensitivity to ulipristal acetateSevere asthma uncontrolled by steroids
| Precautions | Infusion reactions, Infections, Hepatitis B virus reactivation, Progressive multifocal leukoencephalopathy (PML), Vaccinations should be given at least 4 weeks prior to initiation |
| Food/Dietary | No clinically significant food interactions reported. Avoid grapefruit juice as it may increase systemic exposure (based on drug class). |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | ULo (urofollitropin) is not indicated for use in pregnant women. No adequate studies exist. Animal studies show no evidence of teratogenicity, but risk cannot be ruled out. Use only if clearly needed. |
| Fetal Monitoring | Monitor for ovarian hyperstimulation syndrome (OHSS). Monitor serum estradiol levels and follicular development via ultrasound. In case of pregnancy, monitor for multiple gestation and ectopic pregnancy. |
| Fertility Effects | ULo is used for ovulation induction; it can cause multiple follicular development. No known negative impact on fertility. However, it is used to treat infertility. |
| ULO (Umeclidinium) is a long-acting muscarinic antagonist (LAMA) used for maintenance treatment of COPD. Administer once daily via inhalation; do not use for acute bronchospasm. Monitor for anticholinergic effects like urinary retention and narrow-angle glaucoma. Use with caution in patients with severe renal impairment (eGFR <30 mL/min). |
| Patient Advice | Use ULO exactly as prescribed; it is not a rescue inhaler for sudden breathing problems. · Rinse mouth with water after each dose to reduce risk of thrush. · If you miss a dose, skip it and take the next dose at the usual time; do not double up. · Avoid getting the medication in your eyes; if this happens, rinse with water and seek medical help if vision changes occur. · Contact your doctor if you experience worsening breathing, chest pain, or signs of allergic reaction. |